Sildenafil Citrate (sildenafil) NDC 51655-793

NDC codes

FDA NDC Directory

Product NDC (as listed)51655-793Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51655-0793Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51655-793-20	51655079320	20 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (51655-793-20)Marketed from Jan 20, 2022
51655-793-52	51655079352	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (51655-793-52)Marketed from Jan 20, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sildenafil Citrate
Generic name (nonproprietary): sildenafil
Active ingredients: Sildenafil citrate — 20 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Northwind Health Company, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204883
Marketing start: Jan 20, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 5 Inhibitors (Mechanism)
Identifiers: Product ID 51655-793_4973b481-9749-d08d-e063-6294a90a4ee7SPL ID 4973b481-9749-d08d-e063-6294a90a4ee7SPL set ID d9ddfd2a-1961-90f9-e053-2a95a90a7f9bRxCUI 577033UNII BW9B0ZE037
Pharmacologic class: Phosphodiesterase 5 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451655079320 followed by a unit qualifier and the quantity

Package 51655-0793-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 1, 2026.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE Sildenafil tablets are phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). ( 1 ) Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. ( 1 , 14 ) Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204883

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204883
Product	Strength	Form · route	Labeler	Product NDC
Sildenafil Citratesildenafil	Sildenafil citrate 20 mg/1	Tablet, Film coatedOral	Proficient Rx LP	71205-305
Sildenafil Citratesildenafil	Sildenafil citrate 20 mg/1	Tablet, Film coatedOral	Proficient Rx LP	71205-623
Sildenafil Citratesildenafil	Sildenafil citrate 20 mg/1	Tablet, Film coatedOral	Advagen Pharma Ltd	72888-018
Sildenafil Citratesildenafil	Sildenafil citrate 20 mg/1	Tablet, Film coatedOral	TruPharma LLC	52817-295
Sildenafil Citratesildenafil	Sildenafil citrate 20 mg/1	Tablet, Film coatedOral	Northwind Health Company, LLC	82868-094